A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Phase 4 Completed 93 enrolled Kirby Institute Merck Sharp & Dohme LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to treatment early on.

Timeline

Start: 2012-06
Primary completion: 2015-06
Completion: 2015-10

Publications

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon alfa-2b	Protein / enzyme biologic	1.5 ug/kg	Subcutaneous
Subject	Ribavirin	Small molecule	800 mg	Oral
Subject	Ribavirin	Small molecule	1400 mg	Oral

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Summary

Timeline

Publications

Drugs

Indications